Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorhexidine + cetylpyridinium chloride + hydrogen peroxide is a combination antimicrobial mouthwash formulation being investigated for the reduction of dental plaque and the treatment of gingivitis. Chlorhexidine (CHX) is a bisbiguanide antiseptic that binds to bacterial cell walls and disrupts the cell membrane, leading to cytoplasmic leakage. Cetylpyridinium chloride (CPC) is a quaternary ammonium compound that similarly disrupts bacterial membranes and inhibits cell metabolism. Hydrogen peroxide (H2O2) serves as an oxidizing agent that produces free radicals to damage bacterial components and also acts as a whitening agent to mitigate tooth staining often associated with chlorhexidine use. This specific triple combination has been evaluated in Phase 3 clinical trials by the Dental School of the National and Kapodistrian University of Athens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + cetylpyridinium chloride + hydrogen peroxide.